Skip to main content

Codeine / Dexchlorpheniramine / Phenylephrine Dosage

Applies to the following strengths: 10 mg-1 mg-5 mg/5 mL; 9 mg-1 mg-5 mg/5 mL

Usual Adult Dose for Cough and Nasal Congestion

10 mL orally every 4 to 6 hours
Maximum dose: 60 mL in 24 hours

Comments:


Uses: Temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold.

Usual Pediatric Dose for Cough and Nasal Congestion

Less than 12 years: Not Recommended

12 years or older:
10 mL orally every 4 to 6 hours
Maximum dose: 60 mL in 24 hours

Comments:


Uses: Temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold.

Renal Dose Adjustments

Use with caution

Liver Dose Adjustments

Use with caution

Dose Adjustments

Elderly: Use with caution generally starting at the lower end of the dosing range

Precautions

The US FDA has issued a Drug Safety Communication restricting use of prescription codeine pain and cough medicines in children less than 12 years. This update follows previous communications evaluating the potential risks of codeine. Children less than 12 years appear to be at the greatest risk of codeine associated serious adverse events including slowed or difficult breathing and death. The FDA is considering additional regulatory action for over the counter (OTC) combination cough and cold products containing codeine. At this time, it appears prudent to avoid codeine use in all children less than 12 years and avoid use in adolescents between 12 and 18 years who are obese, or have conditions such as obstructive sleep apnea or severe lung disease, which may increase the risk of serious breathing problems.

The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for all opioids intended for outpatient use. The new FDA Opioid Analgesic REMS is a designed to assist in communicating the serious risks of opioid pain medications to patients and health care professionals. It includes a medication guide and elements to assure safe use. For additional information: www.accessdata.fda.gov/scripts/cder/rems/index.cfm


Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule V

Dialysis

Data not available.

Other Comments

Administration advice:


Storage requirements:

General:

Monitoring:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.